Weekly Recap | Natera -1.81%, Signatera lands on TIME listWeekly Review·Oct 17, 2026 at 07:47 AMNTRA-2.91%
Weekly Recap | IOVA.US -6.84%, most brokers rate it buyWeekly Review·Oct 17, 2026 at 07:24 AMIOVA-3.28%
Weekly Recap | Halozyme Therap +10.34%, approaching one-year highWeekly Review·Oct 17, 2026 at 07:17 AMHALO-0.23%
Weekly Recap | SPDR S&P Biotech -6.15%, near the lower end of its rangeWeekly Review·Oct 17, 2026 at 05:20 AMXBI-0.75%
Weekly Recap | IOVA.US +2.85%, most brokers rate it buyWeekly Review·Oct 10, 2026 at 06:49 AMIOVA-3.28%
Weekly Recap | SPDR S&P Biotech -0.43%, clinical wins against profit-takingWeekly Review·Oct 10, 2026 at 05:02 AMXBI-0.75%LABD+2.14%
Weekly Recap | SPDR S&P Biotech -0.39%, busy week of biotech headlinesWeekly Review·Oct 3, 2026 at 05:05 AMXBI-0.75%
Weekly Recap | SPDR S&P Biotech -1.08%, warm sector news unable to lift fundWeekly Review·Sep 26, 2026 at 04:56 AMXBI-0.75%
Weekly Recap | SPDR S&P Biotech +0.33%, mixed biotech tapeWeekly Review·Sep 19, 2026 at 04:23 AMXBI-0.75%
Weekly Recap | SPDR S&P Biotech -4.65%, most brokers rate it buyWeekly Review·Sep 12, 2026 at 05:07 AMXBI-0.75%LABD+2.14%
Weekly Recap | SPDR S&P Biotech +0.88%, constituent names hit 52-week highsWeekly Review·Sep 5, 2026 at 04:31 AMXBI-0.75%
Weekly Recap | SPDR S&P Biotech -2.02%, sector split as FDA win lifts select namesWeekly Review·Aug 29, 2026 at 04:01 AMXBI-0.75%
Weekly Recap | SPDR S&P Biotech +5.29%, AI and cancer vaccine catalysts fire up rallyWeekly Review·Aug 22, 2026 at 06:32 AMXBI-0.75%
